Literature DB >> 31395599

Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of α2-antiplasmin.

Satish Singh1, Aiilyan K Houng2, Guy L Reed1.   

Abstract

Stasis of venous blood triggers deep vein thrombosis by activating coagulation, yet its effects on the fibrinolytic system are not fully understood. We examined the relationship between stasis, fibrinolysis, and the development of experimental venous thrombosis. Effects of stasis-induced deep vein thrombosis and fibrinolysis on thrombosis were examined by inferior vena cava ligation in congenic mice with and without α2-antiplasmin (α2AP), the primary inhibitor of plasmin. Venous thrombus weights were measured and thrombus composition was determined by Martius scarlet blue and immunofluorescence staining. Venous thrombi from α2AP+/+ mice contained plasminogen activators, plasminogen activator inhibitor-1, plasminogen, and α2AP, which changed with thrombus age. Normal, α2AP+/+ mice developed large, occlusive thrombi within 5 hours after ligation; thrombi were even larger in plasminogen-deficient mice (P < .001). No significant thrombus formation was seen in α2AP-/- mice (P < .0001) or in α2AP+/+ mice treated with an α2AP-inactivating antibody (P < .001). Venous stasis activated fibrinolysis, measured by D-dimer levels, in α2AP-/- mice vs α2AP+/+ mice (P < .05). Inhibition of fibrinolysis by the indirect plasmin inhibitor ε-aminocaproic acid or by α2AP restored thrombosis in α2AP-/- mice. In addition to its effects on acute thrombosis, thrombus formation was also markedly suppressed in α2AP-/- mice vs α2AP+/+ mice (P < .0001) 1, 7, and 14 days after ligation. We conclude that experimental venous stasis activates the fibrinolytic system to block the development of venous thrombosis. Suppression of fibrinolysis by α2AP appears essential for stasis-induced thrombus development, which suggests that targeting α2AP may prove useful for preventing venous thrombosis.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31395599      PMCID: PMC6753621          DOI: 10.1182/blood.2019000049

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Virchow and his triad: a question of attribution.

Authors:  Catherine N Bagot; Roopen Arya
Journal:  Br J Haematol       Date:  2008-09-06       Impact factor: 6.998

2.  Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin.

Authors:  Guy L Reed; Aiilyan K Houng; Dong Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

3.  Inferior vena cava branch variations in C57BL/6 mice have an impact on thrombus size in an IVC ligation (stasis) model.

Authors:  J A Diaz; D M Farris; S K Wrobleski; D D Myers; T W Wakefield
Journal:  J Thromb Haemost       Date:  2015-03-13       Impact factor: 5.824

Review 4.  Critical review of mouse models of venous thrombosis.

Authors:  Jose A Diaz; Andrea T Obi; Daniel D Myers; Shirley K Wrobleski; Peter K Henke; Nigel Mackman; Thomas W Wakefield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

5.  Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.

Authors:  S A Siefert; C Chabasse; S Mukhopadhyay; M H Hoofnagle; D K Strickland; R Sarkar; T M Antalis
Journal:  J Thromb Haemost       Date:  2014-09-30       Impact factor: 5.824

6.  Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop.

Authors:  Gary E Raskob; Roy Silverstein; Dale W Bratzler; John A Heit; Richard H White
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

7.  TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.

Authors:  N J Mutch; L Thomas; N R Moore; K M Lisiak; N A Booth
Journal:  J Thromb Haemost       Date:  2007-02-02       Impact factor: 5.824

8.  New insights into the mechanisms of venous thrombosis.

Authors:  Nigel Mackman
Journal:  J Clin Invest       Date:  2012-07-02       Impact factor: 14.808

9.  Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.

Authors:  Susan R Kahn; Ian Shrier; Jim A Julian; Thierry Ducruet; Louise Arsenault; Marie-José Miron; Andre Roussin; Sylvie Desmarais; France Joyal; Jeannine Kassis; Susan Solymoss; Louis Desjardins; Donna L Lamping; Mira Johri; Jeffrey S Ginsberg
Journal:  Ann Intern Med       Date:  2008-11-18       Impact factor: 25.391

10.  Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.

Authors:  S Singh; A K Houng; D Wang; G L Reed
Journal:  J Thromb Haemost       Date:  2016-08-06       Impact factor: 5.824

View more
  11 in total

1.  Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.

Authors:  Sravya Kattula; Yaqiu Sang; Gustaaf de Ridder; Anna C Silver; Emma G Bouck; Brian C Cooley; Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2021-09-06       Impact factor: 5.824

2.  Molecular Detection of Venous Thrombosis in Mouse Models Using SPECT/CT.

Authors:  Annemiek Dickhout; Pieter Van de Vijver; Nicole Bitsch; Stefan J van Hoof; Stella L G D Thomassen; Steffen Massberg; Peter Timmerman; Frank Verhaegen; Rory R Koenen; Ingrid Dijkgraaf; Tilman M Hackeng
Journal:  Biomolecules       Date:  2022-06-13

3.  The effect of resting and compression time post-centrifugation on the characteristics of platelet rich fibrin (PRF) membranes.

Authors:  Yan Wei; Yihong Cheng; Yulan Wang; Xiaoxin Zhang; Richard J Miron; Yufeng Zhang
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

4.  Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism.

Authors:  Hannah Fassel; Huigen Chen; Mary Ruisi; Neha Kumar; Maria DeSancho; Katherine A Hajjar
Journal:  Blood       Date:  2021-04-22       Impact factor: 25.476

5.  Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.

Authors:  Satish Singh; Sofiyan Saleem; Guy L Reed
Journal:  Front Cardiovasc Med       Date:  2020-12-23

Review 6.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

7.  Necroptosis Plays a Crucial Role in Vascular Injury during DVT and Is Enhanced by IL-17B.

Authors:  Yunyan Li; Jianfu Chen; Yuan Yang; Yuxue Wang; Yong Zhang; Yan Zhou; Yan Bao; Zongmei Zhang; Yongping Lu
Journal:  J Immunol Res       Date:  2022-08-19       Impact factor: 4.493

Review 8.  Thrombophilia screening revisited: an issue of personalized medicine.

Authors:  Giuseppe Colucci; Dimitrios A Tsakiris
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

Review 9.  The Fibrinolytic System: Mysteries and Opportunities.

Authors:  Robert L Medcalf; Charithani B Keragala
Journal:  Hemasphere       Date:  2021-06-01

Review 10.  α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Authors:  Yosuke Kanno; En Shu
Journal:  Life (Basel)       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.